Perspectum Diagnostics

Perspectum is a commercial-stage diagnostics company specializing in quantitative MRI-based biomarkers for chronic diseases, primarily in hepatology and metabolic health. Its core platform, LiverMultiScan, and newer multi-organ product, CoverScan, provide non-invasive, quantitative assessments to replace or supplement invasive biopsies. The company leverages a strong research foundation from Oxford and has established commercial partnerships and a growing product portfolio aimed at enabling precision medicine. Recent leadership changes and strategic collaborations indicate a phase of operational evolution and market expansion.

Proprietary quantitative MRI analysis software that extracts multi-parametric biomarkers (e.g., corrected T1/cT1) from standard imaging scans to provide non-invasive, objective assessments of tissue health.

Perspectum competes in the non-invasive diagnostic space against other MRI-based technologies (e.g., MR Elastography), ultrasound-based tools (FibroScan), and a growing array of serum biomarker tests. Its key differentiator is the quantitative, multi-parametric data from standard MRI and the expansion into multi-organ analysis. Competitors include established medtech firms and specialized diagnostic companies focused on liver disease.